We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » FDA Guidances Focus on Trials of Crohn’s Disease, Ulcerative Colitis Drugs
FDA Guidances Focus on Trials of Crohn’s Disease, Ulcerative Colitis Drugs
Trials of drugs to treat Crohn’s disease should add reduction of intestinal inflammation to their symptom-relief endpoints, according to an FDA draft guidance released Thursday in tandem with a draft guidance for conducting ulcerative colitis trials.